Prothena Corporation plc (NASDAQ:PRTA) Q4 2024 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
Earnings call shows EPS and net loss near lower guidance, no share repurchase, and uncertainties in AL amyloidosis treatment. Q&A reveals lack of specifics on critical issues and unclear management responses, indicating potential risks. Although management is optimistic about birtamimab's market potential, the financial metrics and lack of guidance clarity suggest a negative sentiment. Given the small-cap nature of the company, this could lead to a stock price decline of -2% to -8%.
Key Financial Performance
Reported EPS $-1.08 EPS, a decrease from expectations of $-1.02.
Net cash used in operating and investing activities $150.3 million, which is at the low end of guidance range of $148 million to $160 million.
Net loss $122.3 million, which is at the low end of guidance range of $120 million to $135 million.
Cash, cash equivalents, and restricted cash $472.2 million, in-line with guidance of $468 million.
Ordinary shares outstanding Approximately 53.8 million shares.
Estimated net cash used in operating and investing activities for 2025 Expected to be between $168 million and $175 million.
Estimated net loss for 2025 Estimated to be between $197 million and $205 million, which includes an estimated $41 million of non-cash share-based compensation expense.
Expected cash, cash equivalents, and restricted cash at end of 2025 Approximately $301 million, representing the midpoint of the range.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Birtamimab: Currently the only potential treatment for AL amyloidosis that has demonstrated an early survival benefit in a randomized clinical trial. Expected to submit a BLA to the FDA for potential U.S. launch by the second half of 2026.
PRX012: Anti-A-beta program designed for a single injection once-monthly subcutaneous treatment. Initial results expected mid-2025.
PRX123: Dual anti-A-beta and anti-tau vaccine with fast-track designation and IND cleared by the FDA.
PRX019: Received an $80 million payment from BMS for a global license agreement and initiated a Phase 1 clinical trial.
AL Amyloidosis Market: Approximately 16,000 diagnosed and treated AL amyloidosis patients in the U.S., with a significant unmet need for treatments addressing early mortality.
Global Market Opportunity for Birtamimab: Expected to be a multi-billion dollar global market opportunity at peak.
Cash Position: As of December 31, 2024, Prothena had $472.2 million in cash, cash equivalents, and restricted cash.
2025 Financial Guidance: Expected net cash used in operating and investing activities to be between $168 million and $175 million.
Partnerships: Four ongoing clinical partnerships with large pharmaceutical companies to advance potentially transformative medicines.
Commercial Strategy for Birtamimab: Plan to independently commercialize birtamimab in the U.S. and evaluate launch timing in European markets.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Earnings Miss: Prothena Corporation missed earnings expectations with a reported EPS of $-1.08, compared to expectations of $-1.02.
Regulatory Risks: The company is subject to regulatory risks associated with the FDA's approval process for its clinical programs, particularly the Phase 3 AFFIRM-AL trial for birtamimab, which has a defined statistical significance threshold.
Clinical Trial Risks: The success of Prothena's clinical programs, including birtamimab and its Alzheimer’s portfolio, is contingent on upcoming trial results, which may not meet expectations.
Market Competition: Prothena faces competitive pressures in the biotechnology sector, particularly in the treatment of AL amyloidosis and Alzheimer’s disease, where multiple therapies are being developed.
Financial Performance: The company reported a net loss of $122.3 million for 2024, which is at the low end of their guidance range, indicating ongoing financial challenges.
Cash Flow Risks: Prothena expects net cash used in operating and investing activities to increase in 2025, with an estimated net loss of $197 million to $205 million, raising concerns about cash flow sustainability.
Partnership Dependencies: Prothena's reliance on partnerships with large pharmaceutical companies for clinical programs introduces risks related to the performance and decisions of these partners.
Market Access Challenges: The company anticipates challenges in establishing market access and commercial capabilities for birtamimab, particularly in a specialized treatment landscape.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Birtamimab: Birtamimab is the only potential treatment for AL amyloidosis that has demonstrated an early survival benefit in a randomized clinical trial. The primary endpoint in the ongoing Phase 3 AFFIRM-AL trial is time to all-cause mortality, with top-line results expected in Q2 2025.
Alzheimer’s Disease Portfolio: Prothena's Alzheimer’s disease programs, PRX012 and PRX123, are designed to address unmet needs in early symptomatic and presymptomatic patients. Initial results from the Phase 1 ASCENT clinical trials for PRX012 are expected mid-2025.
Commercialization Strategy: Prothena plans to independently commercialize birtamimab in the U.S. by the second half of 2026, targeting a market of approximately 16,000 diagnosed AL amyloidosis patients.
Partnerships: Prothena has four ongoing clinical partnerships with large pharmaceutical companies to advance transformative medicines.
2025 Financial Guidance: Prothena expects net cash used in operating and investing activities to be between $168 million and $175 million for 2025, with an estimated net loss of $197 million to $205 million.
Cash Position: Prothena anticipates ending 2025 with approximately $301 million in cash, cash equivalents, and restricted cash.
Market Opportunity: Birtamimab is projected to be a multi-billion dollar global market opportunity at peak, with a focus on Mayo Stage IV AL amyloidosis patients.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Program: None
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is considered the best – the base and best case scenario into the Phase 3 AFFIRM-AL, both on the primary endpoint as well as key secondary?
A:Management emphasized the significant unmet need in AL amyloidosis and the opportunity for birtamimab to demonstrate a survival benefit, particularly in Mayo Stage IV patients. They believe a p-value of 0.10 would represent a best-case scenario.
Q:How are you thinking about the market opportunity in AL amyloidosis, especially given the concentrated prescriber base?
A:Management highlighted that birtamimab represents a blockbuster opportunity in the U.S. and a multi-billion dollar opportunity globally, especially for patients at high risk of early mortality.
Q:Can you talk about the baseline characteristics of the patients enrolled in AFFIRM-AL, especially with regards to the utilization of daratumumab?
A:Management noted that about 80% of subjects in the AFFIRM-AL study are on daratumumab, and the focus is on Mayo Stage IV patients, who are at the highest risk of early mortality.
Q:What would be a clinically meaningful OS benefit for birtamimab to demonstrate in AFFIRM-AL?
A:Management indicated that a p-value of less than 0.10 would be meaningful for the patient population.
Q:Do you have any visibility on long-term mortality trends beyond the randomized phase of the trials?
A:Management stated that there is no long-term follow-up data available from the PRONTO and VITAL trials.
Q:What drove the treatment emergent deaths on the standard-of-care arm in the Stage 4 analysis from VITAL?
A:Management mentioned that all-cause mortality was considered in the analysis, but did not provide specific details on the causes.
Q:How do you think about demand for the drug going forward if there was a minimum effect size in terms of time to death?
A:Management believes that any statistically significant result would be meaningful due to the significant unmet need in early mortality.
Q:Can you talk about the data that you’ll have in hand by the end of the year for PRX012?
A:Management expects to share initial data from the ASCENT-2 trial, focusing on safety, tolerability, and pharmacokinetics.
Q:How easy are Mayo Stage IV AL patients to find and how long will it take to onboard patients post-approval?
A:Management indicated that these patients are diagnosed and treated quickly, but onboarding will take time due to the need for market education.
Q:How are you thinking about the European path and plan?
A:Management believes the medical need is the same in Europe and expects productive dialogue with regulatory authorities.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on long-term mortality trends beyond the randomized phase of the trials and did not elaborate on the causes of treatment emergent deaths in the VITAL study.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AL trial
APOE
ASCENT
ATTR CM
BMS PRX
Chad
Europe
MTBR
PRX beta
PRX program
Phase trial
Slide
United States
VCD
VITAL trial
amyloid deposit
amyloidosis patient
carrier
center
confidence
daratumumab
deposit organ
light chain
mid
month
opportunity
participant
patient Stage
placebo
point
prasinezumab
readout
regimen
result Phase
signal
significance success
standard care
success value
treatment option
PRTA Transcript
Prothena Corporation plc (PRTA) Q4 2025 Earnings Call Transcript
Unknown2-19
The earnings call reflects a mixed sentiment. Financial performance shows prudent capital utilization but also a significant net loss. The Q&A highlights promising developments in product trials and partnerships, but also reveals management's reluctance to provide detailed guidance, creating uncertainty. The share redemption plan indicates potential shareholder value but lacks immediate impact. Overall, the stock is likely to remain neutral, with no strong catalysts for significant movement. The market cap suggests moderate sensitivity to these factors.
Prothena Corporation plc (NASDAQ:PRTA) Q4 2024 Earnings Call Transcript
Unknown2-21
Earnings call shows EPS and net loss near lower guidance, no share repurchase, and uncertainties in AL amyloidosis treatment. Q&A reveals lack of specifics on critical issues and unclear management responses, indicating potential risks. Although management is optimistic about birtamimab's market potential, the financial metrics and lack of guidance clarity suggest a negative sentiment. Given the small-cap nature of the company, this could lead to a stock price decline of -2% to -8%.
Prothena Corporation plc (PRTA) Q4 2023 Earnings Call Transcript
Positive2-16
The company's financial performance was better than expected, with efficient resource management and strong cash reserves. The Q&A session highlighted positive trial developments, such as strong patient enrollment and promising safety profiles, despite some management evasiveness on specific data updates. These factors, combined with the company's market cap, suggest a positive stock price movement within the 2% to 8% range.
Prothena Corporation plc (PRTA) Q4 2022 Earnings Call Transcript
Neutral2-24
PRTA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
